Cancer du tractus biliaire amplifié par HER2 (~5-15% dans l'ensemble; enrichi en vésicule bili...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-HER2-AMP-CHOLANGIO |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-05-08 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-CHOLANGIOCARCINOMA |
| Sources | SRC-ESMO-BTC-2023 SRC-HERIZON-BTC-01-HARDING-2023 SRC-NCCN-HEPATOBILIARY |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-HER2-SOLID |
|---|---|
| Variante | amplification/expression excessive — IHC 3+ ou (IHC 2+ + ISH amplifié, HER2/CEP17 ≥2,0); ~5-15 % du cancer du tractus biliaire (plus élevé dans la vésicule biliare + CPA extrahépatique que dans la CPA intrahépatique) |
| Maladie | DIS-CHOLANGIOCARCINOMA |
| Niveau ESCAT | IIA |
| Combinaisons recommandées | zanidatamab monotherapy 20 mg/kg IV q2w (2L+ post gemcitabine-based 1L per SRC-NCCN-HEPATOBILIARY) |
| Résumé des faits | HER2-amplified biliary tract cancer (~5-15% overall; enriched in gallbladder + extrahepatic cholangiocarcinoma; ~3-5% intrahepatic CCA): zanidatamab (HER2-targeted biparatopic bispecific antibody) 20 mg/kg IV q2w produced confirmed ORR 41.3% (95% CI 30.4-52.8) in previously treated HER2 IHC 3+ or IHC 2+/ISH+ disease in HERIZON-BTC-01 (Harding et al., Lancet Oncol 2023; n=87). FDA accelerated approval November 2024 for HER2-positive (IHC 3+) BTC ≥2L. ESCAT tier IIA (FDA-approved disease-specific). NCCN category 2A. HER2 testing recommended at diagnosis for unresectable / metastatic BTC per SRC-NCCN-HEPATOBILIARY. Gastric-style scoring (Hofmann 2008 — basolateral / lateral membranous staining ≥10%) is generally applied given basolateral HER2 expression pattern in BTC. |
Notes
ESCAT IIA (FDA-approved disease-specific). HER2 testing (IHC + reflex ISH for IHC 2+) recommended at diagnosis for unresectable / metastatic BTC per SRC-NCCN-HEPATOBILIARY. Gastric-style scoring (Hofmann 2008 — basolateral / lateral membranous staining ≥10%) is generally applied. HER2 amplification frequency varies by anatomic subsite: highest in gallbladder + extrahepatic cholangiocarcinoma (~10-15%), lower in intrahepatic CCA (~3-5%). FDA accelerated approval Nov 2024 based on HERIZON-BTC-01; confirmatory study and traditional approval pending. UA access: zanidatamab not registered in UA (named-patient / EAP only as of 2026-05). Trastuzumab + pertuzumab combination has separate weak evidence in BTC (MyPathway Meric-Bernstam 2021 ORR ~23%) but is not the FDA-approved disease-specific combination — zanidatamab is the disease-specific actionable option.
Utilisé par
No reverse references found in the YAML corpus.